fbpx

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Registration Now Open For Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event (Oct. 13) – “Tackling Our Greatest Health Challenges – COVID-19 and Breast Cancer”

By John F. Heerdink, Jr.
 
In honor of October Breast Cancer Awareness Month, Atossa’s CEO Dr. Steven Quay, M.D., Ph.D. & CFO Kyle Guse will deliver a presentation titled “Atossa Therapeutics: Tackling our Greatest Health Challenges – COVID-19 and Breast Cancer”
 
 

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D. & CFO, Kyle Guse, Esq., will present at Tribe Public’s Zoom Webinar Presentation and Q&A Event scheduled to begin at 8am Pacific/11am Eastern on Tuesday, October 13th. To register to join the complimentary, limited capacity ZOOM-based event, please visit Tribe Public LLC’s website at Atossa.TribePublic.com. Once registered, participants may begin forwarding their questions for Atossa’s management to Tribe Public at http://research@tribepublic.com or share via the ZOOM chat feature during the event.

During this complimentary 30-minute event, Atossa’s management team will deliver a presentation titled,Atossa Therapeutics: Tackling our Greatest Health Challenges – COVID-19 and Breast Cancer. A Q&A session will follow regarding Atossa’s breast cancer development programs and recent progress with its two COVID-19 treatment programs, including AT-301, a nasal spray treatment therapy being developed to potentially help prevent COVID-19 infection, particularly for people in high risk communities and those working in higher-risk areas, including healthcare workers, emergency responders and teachers. Tribe Public’s Managing Member, John F. Heerdink, Jr., will host the event and relay all questions. 

Steven Quay, M.D., Ph.D. is the founder of Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS). He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow in the Chemistry Department at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital and spent almost a decade on the faculty of Stanford University’s School of Medicine. His contributions to medicine have been cited 9,890 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented. His current passions are solving big medical problems: stopping the COVID-19 pandemic and preventing the two million breast cancer cases in the world each year. Dr. Quay’s recently-published and highly acclaimed book titled “Stay Safe: A Physician’s Guide to Keep You and Your Family Healthy During the Pandemic and Beyond” is available at his website http://www.drquay.com/books.

ABOUT TRIBE PUBLIC LLC

Tribe Public LLC is a San Francisco, CA based organization that hosts complimentary worldwide webinar & meeting events in the U.S. Tribe’s complimentary events focus on issues that the Tribe members care about with an emphasis on hosting experts and CEO’s of from publicly traded NYSE and Nasdaq listed companies from all sectors & financial organizations that are seeking to increase awareness of their products, progress and plans. Tribe members primarily include Family Offices, Portfolio Managers, Registered Investment Advisors, & Accredited Investors from more than 15 countries. Tribe members submit their collective interests via Tribe’s complimentary “Wish List” process in order gain the understanding that they are seeking about the industries that care about. Join Tribe Public at Website: http://www.tribepublic.com/.

Post View Count : 762


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us